SHAREHOLDER
David C. Harman focuses his practice on personal injury, mass tort, and class action litigation. David has considerable experience representing individuals in complex products liability cases against some of the largest pharmaceutical and medical device manufacturers in the world. For example, David was significantly involved in the Yaz/Yasmin (Drospirenone) Products Liability Litigation (MDL 2100), representing women who suffered injuries as a result of their use of Bayer’s oral contraceptives. David also helped represent hundreds of children that suffered birth defects caused by the drug Depakote. David has also worked on the Testosterone Replacement Therapy (TRT) Products Liability Litigation (MDL 2545), Fosamax Products Liability Litigation (MDL 1789), and the contaminated Heparin litigation.
Outside of mass torts, David is experienced representing individuals in a variety of personal injury claims involving motor vehicle collisions, trucking accidents, and defective products.
David’s work ethic and tireless representation of his clients has been repeatedly recognized by his peers. From 2014 to the present, David has been recognized by the National Trial Lawyers as one of the Top 40 under 40 Attorneys in Ohio. He has also been selected as a Rising Star by Super Lawyers from 2017-2019 and 2021-2022.
Prior to coming to Burg Simpson, David earned his Juris Doctorate from Case Western Reserve University School of Law in 2011, where he graduated magna cum laude and earned honors in his Litigation Concentration. While in law school, David externed for the Hon. Peter C. Economus, U.S. District Court, Northern District of Ohio and was a member of the school’s National Moot Court Team.